Company Analysis
Sign in

Aura Biosciences, Inc. (AURA)

Nasdaq: AURA · Biological Products, (No Diagnostic Substances) · Boston, MA · filing with the SEC since 2010
Full chart Alerts Compare
Grade4.8
◀ Past 5.3● Present 4.1▶ Future 5.2
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

11 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Aura Biosciences, Inc.’s names, not what it holds today.

Patents granted
11
11 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against none in 2024 and 1 in 2023
Applications published
23
since 2001, to Dec 31, 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'12'13'14'16'17'18'19'20'21'22'23'24
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Aura Biosciences, Inc. its own name
US, as the owner printed on each patent. 4 more under the same name are not counted (printed in GB)
11 granted
18 published
Aura Biosciences, Inc. its own name
named as the applicant on its applications, in US
0 granted
5 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 7, 202311,806,406Virus-like particle conjugates for diagnosis and treatment of tumorsPharmaceuticalsAura Biosciences, Inc.
Sep 7, 202111,110,181Virus-like particle conjugates for diagnosis and treatment of tumorsPharmaceuticalsAura Biosciences, Inc.
Jun 23, 202010,688,172HPV particles and uses thereofPharmaceuticalsAura Biosciences, Inc.
Mar 24, 202010,596,275Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cellsPharmaceuticalsAura Biosciences, Inc.
Mar 17, 202010,588,984Virus-like particle conjugates for diagnosis and treatment of tumorsPharmaceuticalsAura Biosciences, Inc.
May 28, 201910,300,150Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cellsPharmaceuticalsAura Biosciences, Inc.
Jan 15, 201910,179,168HPV particles and uses thereofPharmaceuticalsAura Biosciences, Inc.
Nov 6, 201810,117,947Virus-like particle conjugates for diagnosis and treatment of tumorsPharmaceuticalsAura Biosciences, Inc.
Jan 2, 20189,855,347Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cellsPharmaceuticalsAura Biosciences, Inc.
Aug 8, 20179,724,404HPV particles and uses thereofPharmaceuticalsAura Biosciences, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jul 4, 20242024/0216527VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF TUMORSPharmaceuticalsAura Biosciences, Inc.
Dec 8, 20222022/0387619VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF TUMORSPharmaceuticalsAura Biosciences, Inc. · patent 11,806,406 granted from it
May 19, 20222022/0152218HUMAN PAPILLOMAVIRUS NANOPARTICLE FORMULATIONSPharmaceuticalsAura Biosciences, Inc.
May 19, 20222022/0152217TARGETED COMBINATION THERAPYPharmaceuticalsAura Biosciences, Inc.
Mar 24, 20222022/0088216VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF TUMORSPharmaceuticalsAura Biosciences, Inc. · patent 12,029,794 granted from it
Dec 23, 20212021/0393797VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF TUMORSPharmaceuticalsAura Biosciences, Inc. · patent 11,806,406 granted from it
Sep 23, 20212021/0290778TARGETED COMBINATION THERAPYPharmaceuticalsAura Biosciences, Inc.
Jun 18, 20202020/0188529VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF TUMORSPharmaceuticalsAura Biosciences, Inc. · patent 11,110,181 granted from it
Sep 12, 20192019/0275176VIRION-DERIVED NANOSPHERES FOR SELECTIVE DELIVERY OF THERAPEUTIC AND DIAGNOSTIC AGENTS TO CANCER CELLSPharmaceuticalsAura Biosciences, Inc. · patent 10,596,275 granted from it
May 16, 20192019/0142925HPV PARTICLES AND USES THEREOFPharmaceuticalsAura Biosciences, Inc. · patent 10,688,172 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton AURA · research, not advice